Literature DB >> 15349913

Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients.

Danny Ka-Ho Wong1, Man-Fung Yuen, HeJun Yuan, Simon Siu-Man Sum, Chee-Kin Hui, Jeff Hall, Ching-Lung Lai.   

Abstract

This study examined a signal amplification assay, the Invader assay, for the quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in liver biopsies and sera. DNA was extracted from liver biopsy and serum samples were collected from 16 hepatitis B e antigen (HBeAg)-positive and 36 antibody-to-HBeAg-positive (anti-HBe-positive) chronic hepatitis B patients. The amount of total HBV DNA and cccDNA was measured using the Invader assay. Anti-HBe-positive patients had lower median total intrahepatic HBV DNA (P < .001) and intrahepatic cccDNA levels (P = .001) than HBeAg-positive patients. Intrahepatic cccDNA correlated positively with the total intrahepatic HBV DNA (r = 0.950, P < .001). However, the proportion of intrahepatic HBV DNA in the form of cccDNA was inversely related to the amount of total intrahepatic HBV DNA (r = -0.822, P < .001). A small amount of cccDNA was detected in 39 of 52 (75%) serum samples. Anti-HBe-positive patients had lower median serum cccDNA levels than HBeAg-positive patients (P = .002). Serum HBV DNA correlated positively with intrahepatic total HBV DNA (r = 0.778, P < .001) and intrahepatic cccDNA (r = 0.481, P = .002). In conclusion, the Invader assay is a reliable assay for the quantitation of cccDNA. Serum and intrahepatic total HBV DNA and cccDNA levels become lower as the disease progresses from HBeAg-positive to anti-HBe-positive phase, with cccDNA becoming the predominant form of intrahepatic HBV DNA. Copyright 2004 American Association for the Study of Liver Diseases

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349913     DOI: 10.1002/hep.20353

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.

Authors:  Hai-Ying Lu; Li-Wei Zhuang; Yan-Yan Yu; Chong-Wen Si; Jun Li; Jian-Jun Zhang; Zheng Zeng; Xin-Yue Chen; Zhong-Hou Han; Yong Chen
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

2.  Antiviral therapy may decrease HBx, affecting cccDNA and MSL2 in hepatocarcinogenesis.

Authors:  Xue-Li Jin; Suk Kyun Hong; Hwajung Kim; Sun-Kyung Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

3.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Authors:  Christine I Wooddell; Man-Fung Yuen; Henry Lik-Yuen Chan; Robert G Gish; Stephen A Locarnini; Deborah Chavez; Carlo Ferrari; Bruce D Given; James Hamilton; Steven B Kanner; Ching-Lung Lai; Johnson Y N Lau; Thomas Schluep; Zhao Xu; Robert E Lanford; David L Lewis
Journal:  Sci Transl Med       Date:  2017-09-27       Impact factor: 17.956

4.  New developments in HBV molecular diagnostics and quantitative serology.

Authors:  D Scott Bowden; Alex J Thompson
Journal:  Hepatol Int       Date:  2008-02-13       Impact factor: 6.047

Review 5.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

6.  Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus.

Authors:  Thomas B Lentz; Daniel D Loeb
Journal:  J Virol       Date:  2011-09-07       Impact factor: 5.103

7.  Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice.

Authors:  Zhihua Qi; Gaiyun Li; Hao Hu; Chunhui Yang; Xiaoming Zhang; Qibin Leng; Youhua Xie; Demin Yu; Xinxin Zhang; Yueqiu Gao; Ke Lan; Qiang Deng
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

8.  Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients.

Authors:  Hai-Ying Lu; Li-Wei Zhuang; Yan-Yan Yu; Hadad Ivan; Chong-Wen Si; Zheng Zeng; Jun Li; Dong-Ming Hou; Xin-Yue Chen; Zhong-Hou Han; Yong Chen
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

9.  Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.

Authors:  Danny Ka-Ho Wong; Yasuhito Tanaka; Ching-Lung Lai; Masashi Mizokami; James Fung; Man-Fung Yuen
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

10.  High expression of hepatitis B virus based vector with reporter gene in hepatitis B virus infection system.

Authors:  Shi-Hong Li; Wen-Ge Huang; Bing Huang; Xi-Gu Chen
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.